Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of furmonertinib in EGFR exon 20 insertion-mutated advanced or metastatic non-small cell lung cancer
CTR20221165Phase 2Active
- Sponsor
- Allist Pharmaceuticals
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Primary endpoint: Confirmed objective response rate. Started Sep 2022; status: active.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221165.